Article

Exploiting macropinocytosis for therapeutic intervention in RAS mutant Multiple Myeloma

2025-04-09

Abstract excerpt

Roughly 50% of newly diagnosed multiple myeloma (MM) cases harbor KRAS (25%) or NRAS (24%) mutations with an even greater frequency of these mutations observed at relapse. By and large, mutant RAS-driven MM is more resistant to existing therapies including proteasome inhibitors, immunomodulator drugs (IMiDs), and monoclonal anti-CD38 antibodies. In the present study, we demonstrate that mutant RAS-dependent macrop...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d7e3f501-8788-546a-a6c4-56620cc53c66
DOI: 10.1101/2025.04.04.647098

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Exploiting macropinocytosis for therapeutic intervention in RAS mutant Multiple MyelomaDOI 10.1101/2025.04.04.647098Read

Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma.Semantic proximity Read

Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myelomaSemantic proximity Read

Extracellular vesicles in multiple myeloma: pathogenesis and therapeutic applicationSemantic proximity Read

Design of a novel NanoCAR construct that compares well with a conventional ScFv-based CAR targeting BCMA on multiple myelomaSemantic proximity Read

Stability of c-Myc protein differentiates Ras oncogene addiction and MAPK pathway dependency in Ras-mutant multiple myelomaSemantic proximity Read

Intracellular nanoparticle delivery by oncogenic KRAS-mediated macropinocytosisSemantic proximity Read

Anti-CD38-Targeted Piperazine-Derived Lipid Nanoparticles Overcome Hepatic Clearance for mRNA Delivery to Multiple Myeloma Cells <i>In Vivo</i>Semantic proximity Read

Stimulating macropinocytosis of peptide-drug conjugates through DNA-dependent protein kinase inhibition for treating KRAS-mutant cancer.Semantic proximity Read

Stability of c-Myc protein differentiates Ras oncogene addiction and MAPK pathway dependency in Ras-mutant multiple myelomaSemantic proximity Read

KRAS mutation-driven enhanced macropinocytosis: using albumin as a trojan horse for delivering nanomedicine.Semantic proximity Read

Next generation proteomics with drug sensitivity screening identifies sub-clones informing therapeutic and drug development strategies for multiple myeloma patientsSemantic proximity Read

Novel Anti-B-cell Maturation Antigen Alpha-Amanitin Antibody-drug Conjugate HDP-101 Shows Superior Activity to Belantamab Mafodotin and Enhanced Efficacy in Deletion 17p Myeloma ModelsSemantic proximity Read